Loading…
Champaklal Maganlal Homeo Pharmacy Private Limited, an India-based manufacturer of over-the-counter and homeopathic drugs, failed to comply with current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, resulting in adulterated drug products. The company did not conduct adequate identity testing on incoming components, specifically high-risk glycerin used in formulations at elevated percentages, in violation of 21 CFR 211.84(d)(1). These violations were identified during FDA's review of records submitted in response to a November 2022 section 704(a)(4) records request.